Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Buy
72
HROW Quote, Financials, Valuation and Earnings
Last price:
$36.13
Seasonality move
:
100.6%
Day range:
$33.33 - $34.79
52-week range:
$20.85 - $59.23
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
5.80x
P/B ratio:
22.46x
Volume:
380K
Avg. volume:
416.4K
1-year change:
39.2%
Market cap:
$1.3B
Revenue:
$199.6M
EPS (TTM):
-$0.61
Analysts' Opinion
-
Consensus RatingHarrow has received a consensus rating of Buy. The company's average rating is a Buy based on 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $59.03, Harrow has an estimated upside of 70.84% from its current price of $34.55.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $42.00 representing -21.56% downside risk from its current price of $34.55.
Fair Value
-
According to the consensus of 7 analysts, Harrow has 70.84% upside to fair value with a price target of $59.03 per share.
HROW vs. S&P 500
-
Over the past 5 trading days, Harrow has overperformed the S&P 500 by 9.06% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Harrow does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Harrow has grown year-over-year revenues for 19 quarters straight. In the most recent quarter Harrow reported revenues of $47.8M.
Earnings Growth
-
Harrow earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Harrow reported earnings per share of -$0.50.
Enterprise value:
1.4B
EV / Invested capital:
--
Price / LTM sales:
5.80x
EV / EBIT:
596.35x
EV / Revenue:
6.68x
PEG ratio (5yr expected):
-0.26x
EV / Free cash flow:
-38.76x
Price / Operating cash flow:
335.15x
Enterprise value / EBITDA:
76.23x
Gross Profit (TTM):
$158.6M
Return On Assets:
-6.36%
Net Income Margin (TTM):
-10.19%
Return On Equity:
-35.99%
Return On Invested Capital:
-8.36%
Operating Margin:
-23.48%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $92.6M | $138.7M | $212.9M | $34.6M | $47.8M | |
| Gross Profit | $64.9M | $96.8M | $158.6M | $24M | $32.3M | |
| Operating Income | $1M | -$7.3M | $4.8M | -$6.9M | -$11.2M | |
| EBITDA | -$2.9M | $4.5M | $18.6M | -$5M | -$6.3M | |
| Diluted EPS | -$0.65 | -$0.92 | -$0.61 | -$0.38 | -$0.50 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $40.6M | $62.3M | $51.7M | $125.5M | $169.5M | |
| Total Assets | $56.3M | $97.6M | $217.5M | $295.5M | $364.2M | |
| Current Liabilities | $10.1M | $9.2M | $17.7M | $41.8M | $187M | |
| Total Liabilities | $28.4M | $87.9M | $196M | $235.3M | $308.1M | |
| Total Equity | $27.9M | $9.7M | $21.5M | $60.2M | $56.1M | |
| Total Debt | $13.7M | $71.8M | $168.9M | $184.1M | $220.8M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$7.5M | $7.4M | $2.1M | -$4.6M | $19.7M | |
| Cash From Investing | -$132.3M | -$21.7M | -$33.3M | -$110K | -$212K | |
| Cash From Financing | $117.1M | $63.6M | $29.4M | -$809K | $23K | |
| Free Cash Flow | -$145.8M | -$14.3M | -$36.7M | -$4.7M | $19.5M | |
HROW
Sector
Market Cap
$1.3B
$34.4M
Price % of 52-Week High
58.33%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.01%
1-Year Price Total Return
39.2%
-37.36%
Beta (5-Year)
0.407
0.614
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$33.11
200-day SMA
Buy
Level
$33.93
Bollinger Bands (100)
Buy
Level
24.1 - 30.56
Chaikin Money Flow
Sell
Level
-478.3K
20-day SMA
Buy
Level
$31.88
Relative Strength Index (RSI14)
Buy
Level
64.91
ADX Line
Buy
Level
34.58
Williams %R
Neutral
Level
-36.3151
50-day SMA
Buy
Level
$29.33
MACD (12, 26)
Buy
Level
9.32
25-day Aroon Oscillator
Buy
Level
56
On Balance Volume
Neutral
Level
1.4M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.5611)
Sell
CA Score
(Annual)
Level (-1.5477)
Sell
Beneish M-Score
(Annual)
Level (-1.0343)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (3.004)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company’s FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company’s ophthalmology-focused pharmaceutical compounding business.
Stock Forecast FAQ
In the current month, HROW has received 7 Buy ratings 0 Hold ratings, and 0 Sell ratings. The HROW average analyst price target in the past 3 months is $59.03.
-
Where Will Harrow Stock Be In 1 Year?
According to analysts, the consensus estimate is that Harrow share price will rise to $59.03 per share over the next 12 months.
-
What Do Analysts Say About Harrow?
Analysts are divided on their view about Harrow share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Harrow is a Sell and believe this share price will drop from its current level to $42.00.
-
What Is Harrow's Price Target?
The price target for Harrow over the next 1-year time period is forecast to be $59.03 according to 7 Wall Street analysts, 7 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is HROW A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Harrow is a Buy. 7 of 7 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of HROW?
You can purchase shares of Harrow via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Harrow shares.
-
What Is The Harrow Share Price Today?
Harrow was last trading at $36.13 per share. This represents the most recent stock quote for Harrow. Yesterday, Harrow closed at $34.55 per share.
-
How To Buy Harrow Stock Online?
In order to purchase Harrow stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
